2 Biotech Stocks Struggling Today

INSY stock is pacing for its eighth straight loss

Managing Editor
Mar 19, 2018 at 10:11 AM
facebook twitter linkedin

Cidara Therapeutics Inc (NASDAQ:CDTX) stock is lower today, down 22% to trade at $6.09, despite the biotech company reporting its anti-fungal drug Rezafungin acetate met the main goals of a mid-stage study. Cidara will advance this drug to late-stage trials in the latter half of the year. Even amidst the seemingly upbeat news -- and despite being up more than 20% ahead of the bell -- CDTX stock is now on track for its worst single-day performance since February 2017, and is within a stone's throw from its Aug. 16 record low of $5.60. 

Analysts are firmly on the bullish bandwagon. Of the six brokerages covering CDTX, five rate it a "strong buy." Furthermore, the equity's average 12-month price target of $14.19 represents a 133% premium to its current perch. Continued technical underperformance could prompt analyst downgrades and price-target cuts. 

In addition, Insys Therapeutics Inc (NASDAQ:INSY) stock is also staring at a deficit this morning, down 1.2% to trade at $6.36. The company issued a statement regarding Friday's federal indictment of five New York doctors charged with taking kickbacks from Insys in exchange for prescribing fentanyl-based Subsys. Insys said it will cooperate with authorities to resolve the issues of "inappropriate actions" by the former employees.

INSY shares have shed 34% in 2018 alone, and have been guided lower by their descending 20-day moving average since late January. The equity is currently on track for an eight-day losing streak, and last Friday locked up its worst weekly performance since Jan. 12, and its first three-week losing streak since August. 

It's no surprise, then, that the drug stock is heavily shorted. Short interest increased by 25% since early December, and the 12.18 million shares sold short represents a whopping 65% of INSY's total available float. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners